1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

More De-Risking Required Before Pharma Dives Into Psychedelics

Many Barriers To Overcome

 
• By Kevin Grogan

One of the best-attended sessions at the BIO meeting in San Diego saw psychedelics specialists weighing up the sector's chances of breaking taboos and getting to market.

Brain image
• Source: Shutterstock/Andrus Ciprian

Pharmaceutical companies are steering clear of psychedelics at present but their potential to treat conditions with high unmet medical needs including depression, substance use and pain means that the big players are keeping a close eye on the space.

That was one of the key messages to come out of a panel at BIO International Convention in San Diego...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Interest In PTC’s Sephience Launch Overshadows FDA’s Vatiquinone Rejection

 
• By Alaric DeArment

PTC said it got a complete response letter for the Friedreich’s ataxia drug, with the agency asking for an additional clinical trial.

Post-GLP-1 Patients Are Significant Opportunity, But Response Sees More

 
• By Alaric DeArment

The company will move ahead in testing RDX-002 among overweight and obese patients coming off GLP-1s, but the CEO said antipsychotic-induced weight gain could represent a multibillion-dollar market.

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 
• By Andrew McConaghie

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

Sumitomo Parkinson’s Filing A Pivotal Moment For Japan’s iPSC Ambitions

 
• By Lisa Takagi

Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.

More from Therapy Areas

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 
• By Andrew McConaghie

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.